Navigation and service

BIENNIAL REPORT 2019/2020

Welcome

Welcome

Research

Research

International

International

Regulation

Regulation

Organisation

Organisation

Data & Facts

Data & Facts

22.04.2020 back forward

COVID-19 Vaccines: First Clinical Trial

SARS-CoV-2 (Source: NIAID)

On 22 April 2021, the Paul-Ehrlich-Institut approves the first phase I/II clinical trial of a vaccine candidate against COVID-19 in Germany. BioNTech, a Mainz-based company, is testing a vaccine using the novel mRNA technology. The Paul-Ehrlich-Institut launches a series of virtual press briefings, at which journalists can talk, on an equal footing, to President Prof. Cichutek, experts from the Paul-Ehrlich-Institut and the manufacturers, and receive information on the development, marketing authorisation and safety of COVID-19 vaccines.

Essential work in Times of Pandemic